Literature DB >> 2043724

Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.

T Wikberg1, J Taskinen.   

Abstract

Methods based on reversed-phase liquid chromatography with amperometric detection have been developed for determination of nitecapone, 3-(3,4-dihydroxy-5-nitrobenzylidene)-2,4-pentanedione, a COMT inhibitor, in human plasma and urine. Nitecapone was extracted with ethyl acetate-hexane mixtures from plasma after acidification with hydrochloric acid and from urine as the tetrabutylammonium ion-pair of its diphenylborate derivative. The recoveries of both methods exceeded 70% and the relative standard deviations for within-day precision were less than 4% and 8% at 50 ng ml-1 and at the quantitation limits, respectively. The methods are selective, sensitive and precise enough for determination of 4-5 ng ml-1 of nitecapone in plasma and urine and are thus suitable for the kind of pharmacokinetic studies exemplified in this paper.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2043724     DOI: 10.1016/0731-7085(91)80238-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.

Authors:  S Sundberg; M Scheinin; P Ojala-Karlsson; J Akkila; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.

Authors:  E Schultz; S Tarpila; A C Bäckström; A Gordin; E Nissinen; P Pohto
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.